ArticleThe oncologist2024
Patients' considerations of time toxicity when assessing cancer treatments with marginal benefit.
Article in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Time toxicity in cancer care: a systematic review of definitions and measurement methods.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Cancer patients' experiences of "time toxicity": a qualitative meta-synthesis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- A qualitative exploration of factors that influence engagement with a digital mental health intervention for women with metastatic breast cancer: Finding My Way-Advanced.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Real-World Clinical, Enviro-Logistical and Economic Implications of Sentinel Lymph Node Biopsy Omission in Early Breast Cancer.Annals of surgical oncology · 2026Article
- Characterizing the Objective Time Spent on Health Care Activities in Clinic and at Home for Patients With Cancer.Cancer medicine · 2026Article
- Time Toxicity in Advanced Breast Cancer: Psychological Burden, Psychiatric Vulnerability, and Implications for Patient-Centered Decision-Making.Medicina (Kaunas, Lithuania) · 2026Review
- Digital Patient-Controlled Follow-Up in Palliative Cancer Care: Protocol for a Mixed Methods Feasibility Study.JMIR research protocols · 2026Article
- The experience of time toxicity in cancer patients: a meta-synthesis of qualitative research.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Outcomes of hypofractionated stereotactic radiotherapy for brain metastases: do we treat patients or lesions?BMC cancer · 2026Article
- Care pathways for asymptomatic brain metastases: comparison of healthcare utilization, costs, and outcomes in outpatient versus acute settings.Journal of neuro-oncology · 2026Article
- Withstanding the test of time for patients in oncology clinical trials.The oncologist · 2026Article
- Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.BJUI compass · 2026Article
- Planned time burden for patients participating in phase 2 cancer trials.The oncologist · 2026Article
- Telehealth utilization during the COVID-19 pandemic: comparing breast cancer survivors to non-cancer patients and implications for current practice.Breast cancer research and treatment · 2026Article
- The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer.ESMO open · 2026Review
- Hospice care for Medicaid cancer patients in Puerto Rico: implications on healthcare costs and utilization.JNCI cancer spectrum · 2026Article
- Time-Toxicity Indicators and Mitigation Strategies in Cancer Care: A Scoping Review.Journal of multidisciplinary healthcare · 2026Review
- Time toxicity during palliative chemotherapy for advanced malignancies: a prospective study.BMJ supportive & palliative care · 2025Observational
- Characterizing and Addressing the Financial, Time, and Administrative Burdens of Cancer and its Care.Current treatment options in oncology · 2025Review
- Patient-, care partner-, and clinician-proposed solutions to address the time toxicity of cancer care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEffective techniques for eliciting patients' preferences regarding their own care, when treatment options offer marginal gains and different risks, is an important clinical need. We sought to evaluate the association between patients' considerations of the time burdens of care ("time toxicity") with decisions about hypothetical treatment options.
methodsWe conducted a secondary analysis of a multicenter, mixed-methods study that evaluated patients' attitudes and preferences toward palliative-intent cancer treatments that delayed imaging progression-free survival (PFS) but did not improve overall survival (OS). We classified participants based on if they spontaneously volunteered one or more consideration of time burdens during qualitative interviews after treatment trade-off exercises. We compared the percentage of participants who opted for treatments with no PFS gain, some PFS gain, or who declined treatment regardless of PFS gain (in the absence of OS benefit). We conducted narrative analysis of themes related to time burdens.
resultsThe study cohort included 100 participants with advanced cancer (55% women, 63% age > 60 years, 38% with gastrointestinal cancer, and 80% currently receiving cancer-directed treatment. Forty-six percent (46/100) spontaneously described time burdens as a factor they considered in making treatment decisions. Participants who mentioned time (vs not) had higher thresholds for PFS gains required for choosing additional treatments (P value .004). Participants who mentioned time were more likely to decline treatments with no OS benefit irrespective of the magnitude of PFS benefit (65%, vs 31%). On qualitative analysis, we found that time burdens are influenced by several treatment-related factors and have broad-ranging impact, and illustrate how patients' experiences with time burdens and their preferences regarding time influence their decisions.
conclusionsAlmost half of participating patients spontaneously raised the issue of time burdens of cancer care when making hypothetical treatment decisions. These patients had notable differences in treatment preferences compared to those who did not mention considerations of time. Decision science researchers and clinicians should consider time burdens as an important attribute in research and in clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.